Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis
- 1 June 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (6) , 1673-1682
Abstract
Focal biliary cirrhosis causes significant morbidity and mortality in cystic fibrosis (CF). Although the mechanisms of pathogenesis remain unclear, bile acids have been proposed as potential mediators of liver injury. This study examined bile acid composition in CF and assessed altered bile acid profiles to determine if they are associated with incidence and progression of liver injury in CF-associated liver disease (CFLD). Bile acid composition was determined by gas-liquid chromatography/mass spectrometry in bile, urine, and serum samples from 30 children with CFLD, 15 children with CF but without liver disease (CFnoLD), and 43 controls. Liver biopsies from 29 CFLD subjects were assessed histologically by grading for fibrosis stage, inflammation, and disruption of the limiting plate. A significantly greater proportion of endogenous biliary ursodeoxycholic acid (UDCA) was demonstrated in CFnoLD subjects vs. both CFLD subjects and controls (2.4- and 2.2-fold, respectively; ANOVA, P = .04), and a 3-4 fold elevation in endogenous serum UDCA concentration was observed in both CFLD subjects and CFnoLD subjects vs. controls (ANOVA, P < .05). In CFLD, there were significant correlations between serum cholic acid and hepatic fibrosis, inflammation, and limiting plate disruption as well as the ratio of serum cholic acid/chenodeoxycholic acid to hepatic fibrosis, inflammation, and limiting plate disruption. In conclusion, elevated endogenous UDCA in CFnoLD suggests a possible protective role against liver injury in these patients. The correlation between both cholic acid and cholic acid/chenodeoxycholic acid levels with histological liver injury and fibrosis progression suggests a potential monitoring role for these bile acids in CFLD. (Hepatology 2004;39:1673-1682.)Keywords
This publication has 42 references indexed in Scilit:
- The evolution of liver disease in cystic fibrosisArchives of Disease in Childhood, 1999
- Liver and Biliary Problems in Cystic FibrosisSeminars in Liver Disease, 1998
- Ursodeoxycholic Acid for Liver Disease Associated With Cystic Fibrosis: A Double–Blind Multicenter TrialHepatology, 1996
- Effect of a Medium Dose of Ursodeoxycholic Acid with or without Taurine Supplementation on the Nutritional Status of Patients with Cystic FibrosisJournal of Pediatric Gastroenterology and Nutrition, 1994
- Analysis of risk factors for the development of liver disease associated with cystic fibrosisThe Journal of Pediatrics, 1994
- Ursodeoxycholic Acid Therapy in Cystic Fibrosis—Associated Liver Disease: A Dose–Response StudyHepatology, 1992
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989
- Liver Disease and Common-Bile-Duct Stenosis in Cystic FibrosisNew England Journal of Medicine, 1988
- Hepatobiliary Disease in Cystic FibrosisJournal of Pediatric Gastroenterology and Nutrition, 1982
- Cystic Fibrosis: Its Influence on the Liver, Biliary Tree, and Bile Salt MetabolismSeminars in Liver Disease, 1982